DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status by Flanagan, JM et al.
Flanagan et al,  DNA methylome of familial breast cancer - 1 - 
 
 
DNA methylome of familial breast cancer identifies distinct profiles 
defined by mutation status 
 
James M. Flanagan1,*, Sibylle Cocciardi2, Nic Waddell2, Cameron N. Johnstone2, Anna 
Marsh2, Stephen Henderson1, Peter Simpson3, Leonard da Silva3, kConFab 
Investigators, Kumkum Khanna4, Sunil Lakhani3, Chris Boshoff1 and Georgia Chenevix-
Trench2  
 
1. CRUK Viral Oncology Group, UCL Cancer Institute, London, UK. 
2. Division of Genetics and Population Health, Queensland Institute of Medical 
Research, Brisbane, Australia 
3. Molecular & Cellular Pathology, University of Queensland Centre for Clinical 
Research, University of QLD. Brisbane, Australia. 
4. Division of Cancer and Cell Biology, Queensland Institute of Medical Research, 
Brisbane, Australia 
 
*To whom correspondence should be addressed: 
Dr. James M. Flanagan 
Current Address: Epigenetics Section, Department of Oncology 
Faculty of Medicine, Imperial College London 
8th Floor MRC Cyclotron Building, Hammersmith Hospital 
Du Cane Road, London, UK. W12 0NN 
Ph: +44 2083838328 email: j.flanagan@imperial.ac.uk 
 
Running Title: DNA methylome of familial breast cancer 
Key Words: Familial breast cancer, epigenetics, methylation, microarray, BRCA 
*Manuscript
Click here to view linked References
Flanagan et al,  DNA methylome of familial breast cancer - 2 - 
 
Abstract  
It is now understood that epigenetic alterations occur frequently in sporadic breast 
carcinogenesis, but little is known about the epigenetic alterations associated with 
familial breast tumors. We performed genome-wide DNA methylation profiling on 
familial breast cancers (n=33) to identify patterns of methylation specific to the different 
mutation groups (BRCA1, BRCA2 and BRCAx) or intrinsic subtypes of breast cancer 
(basal, luminal A, luminal B, HER2-amplified and normal-like). We used methylated 
DNA immunoprecipitation (meDIP) on Affymetrix promoter chips to interrogate 
methylation profiles across 25,500 distinct transcripts. Using a support vector machine 
classification algorithm, we demonstrated that genome-wide methylation profiles 
predicted tumor mutation status with estimated error rates of 19% (BRCA1), 31% 
(BRCA2) and 36% (BRCAx), but did not accurately predict the intrinsic subtypes defined 
by gene expression. Furthermore, using unsupervised hierarchical clustering we 
identified a distinct subgroup of BRCAx tumors defined by methylation profiles. We 
validated these findings in the 33 tumors in the test set, and in an independent 
validation set of 47 formalin-fixed, paraffin-embedded familial breast tumors, by 
pyrosequencing and Epityper. Finally, gene expression profiling and SNP CGH array 
previously performed on the same samples allowed full integration of methylation, gene 
expression and copy number data sets revealing frequent hypermethylation of genes 
that also displayed loss of heterozygosity (LOH) but also in genes that show copy 
number gains providing a potential mechanism for expression dosage compensation. 
Together these data show that methylation profiles for familial breast cancers are 
defined by the mutation status and distinct from the intrinsic subtypes.   
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Supplemental material is available online. Raw MeDIP microarrary data are available 
from Gene expression Omnibus (GEO) and processed MeDIP, gene expression and 
copy number data are available for download (accession GSE17125). Raw gene 
expression and copy number data are also available from GEO (accession GSE19177)  
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Introduction 
 
Breast cancer [OMIM 11448] is one of the most common cancers in the Western world 
affecting one in ten women during their lifetime 1. Mutations in the known breast cancer 
susceptibility genes, including BRCA1 [OMIM 113705] and BRCA2 [OMIM 600185], 
account for approximately only 25% of familial breast tumors 2. Expression profiling has 
shown that breast cancers fall into five intrinsic subtypes – luminal A, luminal B, HER2-
amplified, basal and normal-like 3. Most BRCA1-related tumors are of the basal subtype 
4.  However, we have shown that there is considerable heterogeneity among familial 
breast tumors, with almost all five subtypes being found in each mutation class 5. 
 
Epigenetic processes include DNA methylation, histone modifications, chromatin 
structure and non-coding RNA mediated regulation of gene expression 6. Historically, 
DNA methylation studies in cancer have revealed both hypermethylation of promoter 
CpG islands and hypomethylation of repetitive DNA sequences 7.  There are over 90 
candidate genes reported throughout the literature as promoter hypermethylated in 
breast cancers (Pubmeth web resource).    More recently, DNA methylation alterations 
have been studied in breast tumor tissue on a genome wide scale, revealing 
hypermethylated as well as hypomethylated loci, compared to matched adjacent tissues 
8 ; 9. Novak et. al. (2008) interrogated 16 unselected breast tumors, five normal breast 
specimens and several breast cancer cell lines with Affymetrix promoter arrays and 
identified 2033 hypermethylated and 1473 hypomethylated regions in the tumors, 
compared to the whole sections of normal breast. Most of the differentially methylated 
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regions were recurrent, with 90% of them occurring in at least five tumors.  Both the 
hyper- and hypomethylated regions were also clustered in regions of Long Range 
Epigenetic Silencing (LRES) 10, and were frequently found at gene family clusters 
including the proto-cadherin gene cluster on chromosome 5 9; 11. Ordway et al (2007) 
evaluated nine infiltrating ductal breast carcinomas and matching normal tissue with 
custom promoter methylation microarrays and identified 220 loci that distinguished 
tumor from normal. Five of these loci were validated in a series of 230 clinical samples, 
and some showed considerable promise as biomarkers 8. Promoter tiling arrays have 
also been used to evaluate a cell line model of breast cancer metastasis and identified 
differential methylation in genes involved in epithelial-mesenchymal transition and tumor 
cell migration 12.  
 
One previous study suggested that hereditary breast cancers have similar methylation 
to sporadic tumors in 10 candidate genes 13. However, a more recent study investigated 
11 candidate genes (5 overlapping with the previous study) and suggested that BRCA1 
related breast cancers have less methylation than sporadic breast cancers 14. To our 
knowledge, no study has yet performed genome-wide methylation analysis on familial 
breast cancers nor looked for methylation differences between familial breast tumor 
mutation classes. Therefore, we sought to use genome-wide DNA methylation profiling 
of familial breast cancer cases to identify patterns of methylation specific to the different 
mutation groups (BRCA1, BRCA2, non-BRCA1/2 (BRCAx)) which may provide clinically 
relevant diagnostic value. The same tumor DNA samples have been analyzed by gene 
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expression profiling and copy number analysis 5, allowing for the first time a 
comprehensive integrated genomic analysis of familial breast tumors. 
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Materials and Methods 
 
Patient material 
For DNA methylation microarray analysis we analyzed 33 fresh frozen familial tumors 
including BRCA1 (n=11), BRCA2 (n=8) and BRCAx (n=14).  Characteristics of these 
tumors have been described in more detail elsewhere 5. The tumors were collected by 
the Kathleen Cunningham Foundation for Research into Breast Cancer (kConFab), a 
consortium which ascertains multiple-case breast cancer families 15. Ethical approvals 
for recruitment were obtained from the institutional review boards or ethics committees 
at all the sites. Written informed consent was obtained from each participant. The 
BRCAx tumors came from women from high risk families ascertained by kConFab, and 
in each case the tumor donor had undergone full BRCA1/2 mutation testing by full 
sequencing and multiplex ligation-dependant probe amplification. The additional 
validation set of formalin fixed paraffin embedded (FFPE) tumors consisted of BRCA1 
(n=14), BRCA2 (n=13) and BRCAx (n=20) tumors from kConFab. All specimens were 
evaluated by a pathologist for percent neoplasia prior to DNA isolation and were 
selected for DNA analyses if they were >75% tumor after needle macro-dissection. DNA 
was extracted by standard salt extraction and phenol/chloroform protocol.  Estrogen 
receptor (ESR1, [OMIM 133430]), progesterone receptor (PGR, [OMIM 607311]) and 
HER2 (ERBB2, [OMIM 164870]) status, grade and tumor type were available from 
clinical records (Supplementary Table 1). 
 
CGI Methylation Profiling 
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We performed microarray-based DNA methylation analysis using methylated DNA 
immunoprecipitation (MeDIP) on high density Affymetrix tiling microarrays 16. MeDIP 
was performed using the Diagenode MeDIP kit and the manufacturer‟s protocol 
(Diagenode, Leige, Belgium). The Affymetrix GeneChip® Human Promoter 1.0R Array 
is comprised of over 4.6 million probes tiled at an average resolution of 35bp covering 
approximately 10kb around 25,500 transcription start sites (Affymetrix, High Wycombe, 
UK). We performed triplicate MeDIP reactions for each tumor and amplified using 
whole-genome amplification with Genomiphi V2 and the manufacturer‟s protocol (GE 
Healthcare). The triplicates were then pooled for one MeDIP array and one input array 
per sample.  The arrays were hybridized using Affymetrix hybridization reagents, using 
an Affymetrix hybridization oven, and stained/washed using the Fluidics Station 450 
(Affymetrix, High Wycombe, UK). Arrays were scanned using the GeneChip Scanner 
3000 7G with autoloader. Raw data were extracted using GeneChip Operating System 
(GCOS) software from Affymetrix.  
 
qPCR validation 
Quality control of the MeDIP samples prior to microarray analysis was performed using 
qPCR based analysis of enrichment using primers to “spiked in” and inherent controls 
provided with the Diagenode MeDIP kit. These included methylated sequence controls 
(human Alpha satellite and in vitro methylated Arabidopsis DNA) and unmethylated 
controls (human GAPDH promoter [OMIM 138400] and unmethylated Arabidopsis 
DNA). qPCR was performed using an Eppendorf realtime PCR machine and the 
reaction mix contained 1x SYBR green master mix (Applied Biosystems, Foster City, 
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USA) and 0.5mM of each forward and reverse primers in a volume of 30 L. PCR 
cycling consisted of 95oC for 10 min, then 40 cycles of 95oC for 30s, 60oC for 60s, 
followed by a meltcurve analysis.  
 
 
Bisulphite Sequencing 
We have used both pyrosequencing and Epityper based analysis for validation of DNA 
methylation differences. Epityper was used to cover long segments of DNA covering up 
to 50 CpG sites per gene. Pyrosequencing was used for shorter assays over higher 
density CpG regions (4-9 CpG sites).  All primers used in this study are presented in 
Supplementary Table 2. DNA samples were bisulphite converted using EZ-96 DNA 
Methylation-Gold kit using the manufacturer‟s protocol (Zymo Research, Orange, CA). 
Pyrosequencing: All pyrosequencing assays were designed using the PyroQ assay 
design software. A common tag was placed on either the forward or reverse primer 
(depending on the strand to be sequenced) and a common universal biotinylated primer 
was used for all reactions as previously described 17. PCR cycling conditions were 
performed as previously 18. All assays were optimized with fully methylated gDNA 
(100%) (Zymo Research) compared to unmethylated gDNA (0%, whole genome 
amplified DNA (GE Healthcare)). All products were confirmed to be single bands by 
agarose gel electrophoresis. Methylation values were calculated as an average of all 
CpG sites within each assay as determined by the Pyro Q-CpG Software (Biotage, 
Uppsala, Sweden). 
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Epityper: Bisulphite treated DNA (1µL) was used in a 5 µl PCR reaction using 0.2 
µM`T7-promoter tagged reverse primer, 0.2 µM 10mer tagged forward primer, 1.5 mM 
MgCl2, 200 µM dNTP mix, 1x FastStart Taq DNA Polymerase PCR Buffer (Roche 
Applied Science, Penzberg, Germany) and 0.4 U FastStart Taq DNA polymerase 
(Roche Applied Science, Penzberg, Germany). The PCR cycling conditions were 4 min 
at 94°C, followed by 9 cycles of 94°C for 20 sec, 72°C to 62°C (-1°C/cycle) for 30 sec 
and 72°C for 1 min, followed by a further 36 cycles at 62°C annealing temperature. 
Random products were visualized on a 1% agarose gel to confirm single band 
amplification. After Shrimp Alkaline Phosphatase (SAP) treatment, PCR products were 
subjected to T cleavage transcription and RNase A cleavage according to the 
EpiTYPER Application Guide (Sequenom, San Diego, CA), spotted onto a SpectroCHIP 
array and analyzed using the MassARRAY Compact System MALDI-TOF mass 
spectrometer (Sequenom, San Diego, CA). Data were analyzed using EpiTYPER 
software (Sequenom, San Diego, CA). Primers were designed using EpiDesigner 
(Sequenom, San Diego, CA). 
 
Statistical Analysis  
DNA Methylation profiling using MeDIP data: Raw data were analyzed using the MAT 
algorithm which models the baseline probe behavior and normalizes  probe t-value 
score according to a probe sequence based model taking into account the MeDIP and 
input probe values 19.  For transcription start site analysis the MAT output t-values were 
combined for each start site (obtained from USCS genome browser genome build 36) 
+/- 250bp around each start site (n=20527 unique transcripts). These were subdivided 
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into low CpG content promoters (LCPs, n=5997), intermediate CpG content promoters 
(ICPs, n=4544) and high CpG content promoters (HCPs, n=9986) as previously 
described 16. Briefly, HCPs (high-CpG promoters) contain a CpG ratio above 0.75 and 
GC content above 55%; LCPs (low-CpG promoters) contain a CpG ratio below 0.48; 
and ICPs (intermediate CpG promoters) are neither HCPs nor LCPs. These were 
further filtered to the genes that were represented by both MeDIP and gene expression 
data sets to (LCPs, n=4738; ICPs, n=3517; HCPs, n=7982). Support vector machine 
learning was performed using the MLInterfaces package. In brief, the MLearn algorithm 
uses 5-fold balanced cross validation using 80% of the data as a training set to predict 
the remaining 20% of the data, through five iterations, resulting in a prediction for each 
tumor in the data set. We used equal numbers of tumors from each mutation group 
(n=8) or intrinsic subtype (n=10) for each of the multiple iterations. The predictions 
presented are an average of 10 permutations of sample selections of the BRCA1 (8/11) 
and BRCAx (8/14) tumors compared to the BRCA2 (8/8) tumors or basal (10/14) and 
luminal A (10/10) tumors. Significance of hierarchical clusters was calculated using the 
R package „pvclust‟ which computes an approximate unbiased p-value for clusters using 
a multi-scale bootstrap re-sampling method 20. Pvclust was performed with n=1000 
bootstrap with all CpG islands or with n=10,000 with ~1700 most variable loci with 
similar results. Significant clusters were identified with a p-value <0.001. Gene set 
enrichment analysis (GSEA) was performed as previously described using the pre-
ranked gene list approach 21. “Core enrichment” describes the leading edge of the plot 
representing the genes that are most enriched. Autocorrelation analysis (acf) was used 
to determine correlation between neighboring genes to look for genome-wide evidence 
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of long-range epigenetic silencing. The frequency of high methylation in tumors (% of 
tumors with MeDIP t-value >0.5) was calculated for each gene and all genes were 
ordered by their chromosome location, such that each gene was next to its nearest 
gene irrespective of distance between them. Only one representative transcription start 
site was used for genes with multiple start sites.  
Pyrosequencing and Epityper data: Wilcoxon signed rank sum test was used to 
determine statistical significance between groups for all pyrosequencing or Epityper 
DNA methylation data. 
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Results 
 
DNA methylation profiles are defined by mutation status. 
In this study we performed genome-wide DNA methylation analysis using MeDIP on 
Affymetrix human promoter tiling arrays (1.0R) which cover over 25,500 individual 
promoters. We assayed 33 familial breast tumors (11 with BRCA1 mutations, 8 with 
BRCA2 mutations and 14 from nonBRCA1/2 families (BRCAx)) to investigate the 
contribution of mutation status to the tumor DNA methylation profile. These tumors have 
also been profiled using Illumina gene expression and SNP-CGH array for copy 
numbers thus allowing comparisons across all three platforms on the same samples 5.  
Tumor information including hormone receptor status, stage and intrinsic phenotypic 
subtype is provided in Supplementary Table 1. Validation of MeDIP enrichment before 
and after amplification was performed using qPCR for methylated and unmethylated 
controls and the correlation between MeDIP t-value and methylation percentage was 
assessed by pyrosequencing for four genes DHX33 (methylated, [GeneID:56919]), 
GRHL2 (unmethylated, [OMIM 608576]), IGF2 DMR0 (imprinted, [OMIM 147470]) and 
RASSF1A (frequently methylated in breast cancer, [OMIM 605082]) (Supplementary 
Figure 1). These controls show good correlation between the absolute methylation 
percentage and the average MeDIP t-values provided by the microarray (R2>0.5, 
p<0.0001). Interestingly, 15/33 tumors (45%) showed loss of imprinting (LOI) at IGF2 
DMR0 using a previously reported cutoff of <35% methylation for sporadic breast 
cancers 22.  
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Both gene expression and DNA methylation profiles were analyzed to identify the 
number of genes that could differentiate the mutation subgroups or the intrinsic 
subtypes (Figure 1A). For mutation status groups, comparing BRCA1 tumors to BRCA2 
and BRCAx tumors, the methylation profiles identified 822 significant genes (p.fdr<0.05, 
F-test), compared to only 47 significant (p.fdr<0.05, F-test) genes identified in the gene 
expression profiles.  When these data were broken down to promoter classes based on 
the CpG ratio (defined by 16 and in Materials and Methods, see Supplementary Figure 
2), we observed that high density CpG island promoters contribute most to the 
differences between mutation groups (p=7.15e-37, chi-squared test) whereas gene 
expression profiles on the other hand (with only 47 significant genes) were not biased 
(p=0.517, chi-squared test). In contrast to the mutation groups, analysis of intrinsic 
subtypes identified 2811 genes that were significantly different (p.fdr<0.05, F-test) in the 
gene expression profiles between basal and luminal A breast tumors, but the MeDIP 
methylation profiles did not identify any significant (p.fdr<0.05) differences between 
basal or luminal breast tumors.   
 
We further validated this finding by using a support vector machine (svm) classification 
algorithm to predict the mutation status or intrinsic subtype based on either the gene 
expression profiles or the MeDIP methylation profiles (Table 1).  This algorithm contains 
a balanced 5-fold cross-validation system which uses 80% of the data as a training set 
to predict the remaining 20% of the data, through five iterations, resulting in a prediction 
for each tumor in the data set.  As expected, gene expression data correctly predicts 
intrinsic subtype with 100% accuracy, and predicts BRCA1 mutation with 90% accuracy, 
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mostly due to the fact that BRCA1 tumors are also predominantly basal tumors. The 
GEM also predicts BRCA2 tumors correctly 55% of the time. However, the gene 
expression profiles fail to predict BRCAx tumors. This is consistent with previous studies 
23. Conversely, the MeDIP methylation profiles fail to predict the intrinsic subtypes but 
prediction of mutation classes is improved by consideration of MeDIP methylation 
profiles. Methylation pattern predicted BRCA1, BRCA2 and BRCAx tumors with 
estimated error rates of 19%, 31% and 36%, respectively, which is more accurate than 
the prediction error rates from gene expression profiles (11%, 44%, 71% for BRCA1, 
BRCA2 and BRCAx, respectively). The most interesting improvement is the marked 
increase in prediction of BRCAx tumors; from 71% error using gene expression profiling 
(more than would be expected by chance, 66% error), down to 36% using methylation 
profiling.  This can be also represented as the percent gain which is the improvement of 
the prediction over random chance (%expected) which shows 30% gain for MeDIP 
prediction of BRCAx compared to the 4.5% loss of prediction over random chance for 
gene expression predictions. 
 
Hierarchical clustering of promoter methylation patterns of the 822 genes that defined 
the mutation groups shows a distinct group of BRCA1 tumors and a less defined cluster 
of BRCA2 and BRCAx tumors (Figure 1B). We performed pyrosequencing-based and 
MALDI-TOF-based (Epityper) methylation analysis for eight of these genes including 
one frequently hypermethylated gene, RASSF1A, and seven additional genes (SGK1 
[OMIM 602958], LRRC55 [GeneID: 219527], LHCGR [OMIM 152790], PKD2 [OMIM 
173910], GRAMD1C [GeneID: 54762], DA103059 [hypothetical] and HTR6 [OMIM 
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601109]) in the 33 frozen tumor samples from the test set. These genes were picked 
from the list of 822 genes that defined the mutation groups.  Five of these eight genes 
(RASSF1A, SGK1, LRRC55, LHCGR and PKD2) showed statistically significant 
differences between mutation groups in the original test set (n=33) (Figure 1C) and, 
even more so, in the validation set of FFPE tumors (n=47) (Figure 1D). The only genes 
that were not validated in the FFPE tumor panel were GRAMD1C, DA103059 and 
HTR6 (Supplementary Figure 3). The LHCGR gene was analyzed by both 
pyrosequencing and Epityper with good correlation over the overlapping sequence 
(r2=0.689, p<0.0001). 
 
DNA methylation profiles define BRCAx subgroups 
Given that BRCA1 breast tumors showed a specific methylation profile, we examined 
the methylation patterns in BRCAx tumors to determine whether subgroups could be 
delineated that might reflect germline mutations in the same genes or pathways. Using 
unsupervised hierarchical clustering of the 14 BRCAx tumor samples across all 16237 
genes with a multi-scale bootstrap re-sampling we identified a subgroup of five tumors 
that significantly clustered together (p<0.0001) (Figure 2A-B). These five tumors 
included two basal tumors, two luminal A and one luminal B tumors suggesting that this 
cluster is not defined by the intrinsic subtypes. We identified 156 genes that significantly 
differentiate this group, designated BRCAx-a, from the remaining nine tumors which are 
designated BRCAx-b (Supplementary Table 3). We validated three of these genes, 
HTR6, LHCGR, and GEMIN8 [GeneID: 54960] in both tumor panels (Figure 2C-D). In 
the fresh frozen tumor panel (n=33) we observed a significant increased methylation in 
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the BRCAx-b group (median methylation of 47.9%) compared to the BRCAx-a group 
(12.3%), (p=0.016, T-test) in the promoter CpG island of the LHCGR gene. In the HTR6 
gene we observed regions of significantly higher methylation in the BRCAx-b group 
(57.8%) compared to the BRCAx-a group (34.5%). In GEMIN8 we observed significantly 
increased methylation in the BRCAx-a group (15.9%) compared to the BRCAx-b group 
(6.5%). We were unable to clearly define two subgroups in the FFPE tumor panel 
(n=47) based on these three genes alone; however we did observe bimodal distribution 
of methylation in each of these genes potentially indicative of different groups (Figure 
2D). 
 
Validation of previous findings in sporadic breast cancer 
Until recently the majority of DNA methylation studies have identified individual genes or 
small sets of candidate genes that are hypermethylated in breast cancers with varying 
frequencies.  With our genome-wide data were able to validate previous findings such 
as hypermethylation of various candidate genes in breast cancer and regions of long 
range epigenetic silencing (LRES), and perform fine mapping of regions of 
hypermethylation.  
 
Using gene set enrichment analysis we investigated a list of genes that were previously 
identified as hypermethylated in breast cancer in greater than 20% of tumors and that 
were also represented on the microarray (n=72, Supplementary Table 4) (Figure 3A-B). 
The reported hypermethylated genes are indeed enriched in the MeDIP microarray 
analysis (p=0.042) and we identified 38 genes in the core enrichment that are most 
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frequently methylated in the familial breast cancers (Supplementary Table 4), with the 
strongest enrichment in BRCA1 tumors (p=0.044). We identified the genes, including 
HRAS [OMIM 190020], CXCL1 [OMIM 155730], GREM1 [OMIM 603054], CDCP1 
[OMIM 611735] and RB1 [OMIM 180200] from this list that significantly differentiate the 
mutation subgroups (Figure 3C-D) and have presented detailed Epityper-based 
validation of the Gremlin 1 gene (GREM1) (Figure 3E). In this gene we observed higher 
methylation in the BRCA2 (median methylation 30.8%) and BRCAx tumors (25.8%) 
compared to the BRCA1 tumors (19.9%). 
 
Long range epigenetic silencing has been reported previously in sporadic breast cancer 
and in colorectal cancer [OMIM 114500] and suggests that there may be a relationship 
between frequently methylated genes in “gene family clusters” or on nearby 
chromosomal locations 9; 11. We used an autocorrelation analysis to look for genome-
wide evidence of LRES in familial breast tumors. We show that there are over 1500 
genes that are frequently methylated (MeDIP t-value >0.5) in more than 30% of tumors 
(Figure 4A, n=33) and that there is a statistically significant autocorrelation between any 
gene and up to 3 nearest neighbors (Figure 4B).  
 
The high density array allows for fine mapping of DNA methylation differences using a 
probe-wise analysis and we have used this approach to validate ESR1 (ER 
methylation. Previous studies have shown that five individual CpG dinucleotides in the 
ESR1 promoter were more methylated in BRCA1 tumors compared to ER-negative 
tumors and suggested that this may be an important factor in transcriptional repression 
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of this gene in BRCA1-linked breast cancers 24. We have mapped the critical region of 
hypermethylation in BRCA1- linked ER negative tumors to a 147bp region (Region 2) of 
the CpG island containing 20 CpG sites (chr6:152171256-152171402, NCBI build 36.1) 
(Supplementary Figure 4).  We further validated this in our samples using 
pyrosequencing showing median methylation of 10.6% in BRCA1 ER negative tumors 
compared to 7.5% in the other ER negative tumors (p=0.0056).    
 
Integration of methylation, copy number and gene expression data  
This data set represents the first fully integrated analysis of familial breast tumors with 
genome wide DNA methylation, copy number and gene expression data.  For each 
tumor, every gene was scored as either overlapping with regions of homozygous 
deletion (HD), loss of heterozygosity (LOH), copy neutral LOH, copy gains (GAIN) or no 
change (diploid) in that tumor. For each gene the median MeDIP t-value was then 
calculated from tumors in each of the five copy number groups (if present) using the 
diploid tumors as a reference level for that gene (Figure 5). Hierarchical clustering 
identified two groups of genes, the first that contained both LOH and high methylation in 
tumors and the second that contained copy number gains and high methylation in 
tumors (Figure 5A).  This was observed in 607/4921 (12.3%) genes with LOH and 
1032/9070 (11.4%) genes with copy number gains. In contrast, the methylation of genes 
in copy neutral LOH regions was only higher than in diploid tumors for 129/15213 
(0.8%) genes. This is statistically supported by chi squared analysis, 2=407.2, p<2.2e-6 
(Supplementary Table 5). Similar results were obtained when tumors were separated 
into mutation groups (Supplementary Figure 5). Furthermore, the median methylation (t-
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values) for all genes with LOH was 0.72 (range 0.5 - 4.0) and copy-gain was 0.70 
(range 0.5 – 6.3) which were both significantly higher than copy neutral LOH genes with 
a median of 0.60 (range 0.5 – 1.3) (Figure 5B). Gene expression of these groups shows 
that genes within regions of LOH and high methylation more often have decreased 
expression (p=0.00022) and genes within regions of copy gain often maintain higher 
expression (p=1.7e-5), albeit a very modest median increase, 0.08 (log2  gene 
expression, Figure 5C). 
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Discussion 
 
Hypermethylation of promoter CpG islands occurs frequently in numerous genes in 
almost all human cancers 25. Genome-wide hypomethylation is also frequently observed 
in tumor cells compared to normal tissue 25. Which, if any, of these frequent epigenetic 
changes are early “driving” epimutations, or late event “passenger” epimutations is not 
clear, nor is the mechanism of how these alterations occur known. In this study we have 
shown that different germline mutations can lead to very different epigenetic profiles in 
breast tumors. Methylation markers might therefore be useful as an additional tool for 
predicting mutation status of tumors, prior to confirmation by sequence analysis, and 
distinguishing pathogenic from neutral variants in BRCA1 26; 27 
 
An epigenetic role for BRCA1 has been proposed due to its binding to HDAC1 [OMIM 
601241] and HDAC2 [OMIM 601241] and chromatin remodelling complexes 28; 29. 
However, a direct role for BRCA1 in DNA methylation has not yet been investigated. 
There are conflicting reports about the level of methylation in BRCA1 mutated tumors 
compared to sporadic breast tumors 13; 14. We showed that the BRCA1 tumors have the 
most distinct genome-wide DNA methylation profiles with the highest svml predictions 
and most significant clustering. In the genes that we have validated in both sets of 
tumors (e.g. RASSF1A, SGK1, HTR6, LHCGR, PKD2 and others) we observed lower 
methylation levels in the BRCA1 breast tumors compared to the BRCA2 and BRCAx 
tumors.  Low levels of methylation have been observed in other genes in BRCA1 
tumors, best exemplified by HIN1 (SCGB3A1, [OMIM 606500]) 13; 14; 30; 31. Together, 
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these data are consistent with a role for BRCA1, direct or indirect, in de novo 
methylation of these genes or in the spreading/maintenance of methylation marks, a 
function that is likely to be absent in BRCA1 mutated tumors. Therefore, further 
investigation of the role of BRCA1 in DNA methylation is warranted. Recently, DNA 
demethylation has been shown to be cyclical in the oestrogen responsive promoters 
dependant on deamination/glycosylation and base excision repair pathways suggesting 
a rapidly changing DNA methylation state 32; 33. There is now compelling evidence that 
DNA demethylation involves DNA repair via a 5-meC deaminase, Activation-induced 
deaminase (AICDA, [OMIM 605257]), and a G:T mismatch-specific thymine 
glycosylase, Mbd4 [OMIM 603574], and is promoted by GADD45 [OMIM 126335] 
proteins through physical interactions with both AICDA and Mbd4 34; 35. These data 
suggests that the enzymatic reaction maintaining the DNA methylation is in a fine 
balance that can be shifted rapidly and that fully functional DNA repair pathways are 
required.  Interestingly, although BRCA1 transactivates GADD45 promoter in response 
to DNA damage, it has been reported to repress GADD45 transcription in unperturbed 
cells through interaction with CtIP (RBBP8 [OMIM 604124]), a co-repressor 36. Thus, it 
is possible that increased GADD45 expression in the absence of BRCA1 may account 
for hypomethylation seen in BRCA1 tumors compared to other familial tumors.  
 
Gene expression profiling of sporadic and familial breast tumors can categorise them 
into defined pathological and clinically different intrinsic subtypes including basal tumors 
(often triple negative, BRCA1 mutated tumors and poorer prognosis), HER2-amplified 
tumors, and luminal tumors (hormone receptor positive and better prognosis) 3; 5. In this 
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study we have attempted to use the DNA methylation profiles to recapitulate the 
clustering into these intrinsic subtypes. However, we observed no significantly different 
genes between the basal and luminal groupings, thus it is not surprising that the svm 
prediction using the methylation profiles were unable to identify whether the tumors 
were basal or luminal breast tumors. We do not discount the possibility that larger 
numbers of tumors may identify statistically significant differences between intrinsic 
subtypes. Since BRCA1 tumors were accurately predicted, and almost all BRCA1 
tumors are basal tumors, one might assume that the methylation profiling should have 
predicted the basal tumors. However, there were an additional four basal tumors that 
were BRCAx tumors, and these tumors had very different methylation profiles to the 
BRCA1 tumors, which accounts for the poor prediction of basal tumors. These data 
suggest that the differences in gene expression that define these intrinsic subgroups are 
not regulated by differential DNA methylation. 
 
We have recently shown by gene expression profiling that, like sporadic tumors, BRCAx 
tumors are heterogeneous and manifest all five intrinsic subtypes 5. However, we have 
found that DNA methylation profiling predicted a higher number of BRCAx tumors, with 
64% accuracy, than gene expression data (29% accuracy). Furthermore, when we 
performed unsupervised hierarchical clustering on these samples we found a subset of 
tumors that clustered together in a highly significant branch of the cluster (p<0.0001). 
These five tumors included two basal, two luminal and one HER2 tumor, indicating that 
these groupings are not reliant on the intrinsic subtypes. Given that the BRCA1 tumors, 
which all harbor mutations in the same gene, have a distinctive methylation profile we 
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hypothesize that this subgroup of BRCAx tumors with similar profiles may harbor 
mutations in the same gene or same pathway. The methylation of genes such as HTR6, 
LHCGR, and GEMIN8 in which we have validated the differences in these groups may 
be used in future studies to subdivide this heterogeneous tumor group into a subclass 
that may be more homogenous and may increase the sensitivity of linkage analysis or 
high throughput sequencing mutation screening for the identification of novel breast 
cancer susceptibility genes. However, we note that only 14 BRCAx tumors were profiled 
in this study. Although validation in the 47 FFPE tumors showed bimodal distribution of 
methylation for these genes the existence of BRCAx subtypes with different methylation 
profiles needs to be further validated with a larger panel of genes in more BRCAx 
tumors, including sets from within the same family in order to determine whether there 
might be a genetic basis to such methylation subtypes.  
 
The genome-wide nature of our methylation analysis has allowed us to investigate the 
methylation of any gene with high probe-level resolution (~35bp resolution). We used 
this resolution to validate the fine mapping of increased methylation changes in the first 
intron of the ESR1 gene in BRCA1 tumors compared to non-BRCA1 tumors 24. This has 
been proposed as one specific mechanism by which BRCA1 tumors alter ESR1 
expression, thereby altering the response to anti-oestrogen therapies and may account 
for a difference between BRCA1 and non-BRCA1 basal tumors 24; 37. BRCA1 is also 
recruited to the ESR1 promoter by Oct1, where it is required for ESR1 expression 38. It 
is not yet known if this binding of BRCA1 to the promoter is responsible for the change 
in CpG island methylation. 
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We performed validation of variable methylation levels in numerous genes including 
RASSF1A, SGK1, PKD2, HTR6, LHCGR and GEMIN8. We hypothesise that differential 
methylation of these genes may contribute to phenotypic differences between these 
mutation classes. For example, we observed increased methylation of the luteinizing 
hormone/ choriogonadotropin receptor (LHCGR) in BRCA2 and BRCAx compared to 
BRCA1 tumors. This gene is regulated by DNA methylation and histone modifications 
and its mRNA is undetectable in up to 65% of unselected breast cancers 39; 40. 
Furthermore, the expression of LHCGR is increased in more invasive breast tumors, 
and thus the decreased methylation of LHCGR we observed in BRCA1 tumors may 
contribute to their increased aggressiveness compared to other tumors 41; 42. PKD2 is a 
membrane bound protein involved in tubulogenesis 43. Increased methylation of PKD2 
in BRCA2-related breast tumors may, therefore, promote the increased tubular or 
tubulo-lobular morphology observed in BRCA2 tumors compared to other tumors 44. The 
serum- and glucocorticoid-inducible kinase 1 (SGK1) is a serine/threonine protein 
kinase that is involved in cellular stress and may have an important role in breast tumor 
aggressiveness 45. Furthermore, it is induced in a p53-dependent manner following DNA 
damage and is activated by the mTOR pathway 46; 47. Our finding that SGK1 is less 
methylated in BRCA1 mutated tumors is consistent with the increased activity of the 
mTOR signaling pathway observed in basal-like breast cancers 42; 48. Further 
investigation of the role of methylation of these genes in breast carcinogenesis is 
warranted. 
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We have generated for the first time a complete data set of DNA methylation, gene 
expression and copy number variation on 33 familial breast tumors covering 16237 
gene transcripts (freely available resource – GEO accession GSE17125). We did not 
observe a strong genome-wide correlation between gene expression and methylation. 
This is not surprising given that the majority of genes have unmethylated promoters 
despite differential gene expression regulated by transcription factors and other 
regulatory mechanisms. However, we could identify ~800 genes where gene expression 
was significantly inversely correlated with DNA methylation (Supplementary Table 5). 
We did observe a strong relationship between methylation and copy number with a 
significant number of genes showing both LOH and increased methylation which 
suggests that these genes conform to the Knudson two-hit hypothesis for tumor 
suppressor genes 49. In addition we observed a large number of genes that show copy 
number gain and increased methylation which we hypothesize may be a mechanism for 
dosage compensation to reduce the level of expression of amplified genes. 
 
In summary, we have shown that methylation profiles for familial breast cancers are 
defined by the mutation status and are distinct from the intrinsic subtypes. This finding 
requires independent confirmation in a larger panel of familial tumors. Finally, we have 
provided a novel resource integrating genomic analysis of DNA methylation, gene 
expression and copy number changes which will be useful for future genomic research 
in familial breast cancers.  
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Figure and Table Legends   
 
Figure 1. DNA methylation profiles of BRCA1, BRCA2 and BRCAx tumors. A) 
Percentage of genes that pass the FDR adjusted p-value cutoff of p<0.05 in an F-Test 
testing for differences between mutation subgroups (BRCA1 vs BRCA2 vs BRCAx) or 
for intrinsic subtypes (Basal vs Luminal A) across all genes. DNA methylation data 
(meDIP) was compared to gene expression microarray data (GEM) for all genes, or 
broken down to LCPs, ICPs and HCPs (see Supplementary Figure 2). For mutation 
status groups the methylation profiles identified 822 significant (p.fdr<0.05) genes (112, 
124, 586 for LCP, ICP and HCP respectively) compared to 47 significant (p.fdr<0.05) 
genes (11,13, 23) in the gene expression profiles. The significant genes in the medip 
profiles are biased towards the HCPs (p=7.15e-37, chi-squared test) while the GEM 
profiles are not (p=0.517, chi-squared test). For intrinsic subtypes the gene expression 
profiles identify 2811 significant (p.fdr<0.05) genes (606, 634, 1571 for LCP, ICP and 
HCP respectively) while the methylation profiles did not identify any significant 
(p.fdr<0.05) differences. B) Heatmap and clustering of 822 significant (p.fdr<0.05) 
differences between 33 tumors representing mutation subgroups indicated on the right 
index: BRCA1 (red, n=11), BRCA2 (green, n=8) and BRCAx (blue, n=14), reveals a 
distinct cluster of BRCA1 tumors compared to BRCA2 and BRCAx tumors. BRAC2 and 
BRCAx tumors do not divide into separate clusters. The index on the left shows the 
intrinsic subtypes Basal (red, n=14), Luminal A (blue, n =10), Luminal B (green, n=4), 
HER2 (yellow, n=4) and Normal-like (grey, n=1). C) Bisulphite sequencing analysis of 
RASSF1A, SGK1, LRRC55, LHCGR and PKD2 in 33 fresh frozen tumors. The median 
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methylation levels are indicated by the red line. Genomic locations for the regions 
presented are from Human Mar. 2006 Assembly (hg18). Stars indicate statistically 
significant differences between groups at p<0.05 and p<0.01 as indicated, wilcoxon 
signed rank sum test. D) Validation of methylation differences in RASSF1A, SGK1, 
LRRC55, LHCGR and PKD2 in the 47 formalin fixed paraffin embedded breast tumor 
DNA samples. 
 
Figure 2. Methylation profiling reveals a distinct subgroup of BRCAx tumors. A) 
Unsupervised heirarchical clustering of the 14 BRCAx tumor samples across all 16237 
genes using multiscale bootstrap resampling to generate p-values for clusters (pvclust). 
Clusters with p<0.0001 are boxed in red. Samples are labeled with their intrinsic 
subtype to show that the groupings are not related to the tumor phenotype. B) Heatmap 
and clustering of 156 significant (p.fdr<0.05) differences between the BRCAx-a 
subgroup (dark blue) compared to the remaining tumors (pale blue, termed BRCAx-b) 
shows that the majority of differences (136/156) are increases in methylation in BRCAx-
b. The full list of genes is presented in Supplementary Table 2. C) Bisulphite 
sequencing validation of GEMIN8, HTR6 and LHCGR comparing BRCAx-a subgroup to 
the BRCAx-b subgroup. The median methylation levels are indicated by the red line. 
Genomic locations for the regions presented are from Human Mar. 2006 Assembly 
(hg18). Stars indicate statistically significant differences between groups at p<0.05 and 
p<0.01 as indicated, wilcoxon signed rank sum test. D) Validation of methylation 
differences in GEMIN8, HTR6 and LHCGR in 47 formalin fixed paraffin embedded 
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breast tumor DNA samples. Distribution histograms are presented below to show the 
bimodal distribution of methylation for these genes. 
 
Figure 3. Validation of previously identified hyper-methylated genes in breast 
cancer. A) Gene set enrichment analysis (GSEA) comparing a list of genes that are 
commonly hypermethylated in breast cancers (n=72) to the 16237 genes pre-ranked on 
medip t-values averaged across all tumors (black line), or separated into BRCA1 (red), 
BRCA2 (green) or BRCAx (blue) tumors.The nominal p-value estimates the statistical 
significance of the enrichment score for a single gene set using a random permutation 
of the gene list. B) GSEA of all breast tumors (black line in Fig4A) showing each of the 
90 genes represented black bars. This analysis shows enrichment (p=0.042) of the 
hypermethylated genes across the whole data set with a core set of 38 genes 
significantly enriched (p<0.0001) amongst the frequently methylated genes 
(Supplementary Table 3 – Core hypermethylated genes).  C) T-test for intergroup 
analyses comparing BRCA1 to BRCA2, BRCA2 to BRCAx or BRCAx to BRCA1, 
presented as –LOG(10) p-values. Bars above 1.3 (p=0.05) indicate significant 
differences in methylation between the groups for 28 of these genes. D) Representative 
examples of genes that differentiate tumors based on mutation status. MeDIP t-values 
presented as Box and Whisker plots representing median (centre line), interquartile 
range (box), and 95th percentiles (whisker), and samples outside this range are 
represented as points. E) Epityper validation of GREM1 comparing 33 familial breast 
tumors representing mutation subgroups BRCA1 (red, n=11), BRCA2 (green, n=8) and 
BRCAx (blue, n=14). Presented is the mean methylation at each CpG site (or CpG 
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cluster) across the amplicon (+/- s.e.m.). The line between sites indicates contiguous 
CpG sites. Genomic location for the region presented is from Human Mar. 2006 
Assembly (hg18). 
 
Figure 4. Autocorrelation between frequently methylated genes in familial breast 
cancer. A) Histogram of the frequency of methylation in tumors (percent of tumors with 
medip t-value > 0.5) across all unique genes showing 1581 genes methylated in >30% 
of tumors. B) All genes were ordered by their chromosome location, such that each 
gene was next to its nearest gene. Only one representative transcription start site was 
used for genes with multiple start sites. Autocorrelation analysis of the frequencies of 
methylation for each gene shows increased autocorrelation (> 95% confidence interval, 
blue dotted line) between any gene and its next three neighboring genes showing 
evidence for long-range epigenetic silencing (LRES) in clusters up to 4 genes.  
 
Figure 5. Copy Number versus Methylation reveals frequent methylation in 
tumors with LOH or copy number gains. A) Heatmap of median methylation levels 
(medip t-values) for each copy number group. For each gene (n=16237) tumors were 
broken down into copy number groups (y-axis) of tumors showing either homozygous 
deletion (HD, n=653), loss of heterozygosity (LOH, n=4921), normal diploidy (n=16237), 
copy neutral LOH (n=15213) or gains (n=9070). This shows 607 (12.3%) genes with 
increased methylation in the tumors that show LOH compared to the normal diploid 
tumors and 1032 (11.4%) genes with increased methylation in the tumors that show 
copy number gains compared to diploid tumors. The methylation of genes in copy 
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neutral LOH regions were not significantly different to diploid tumors with only 123 
genes with increased methylation (0.8%). Blue = increased methylation, 
Yellow=decreased methylation. B) Boxplot of median methylation levels (y-axis,medip t-
values) for the genes that have LOH and increased methylation (compared to diploid 
tumors), copy neutral LOH and increased methylation, or copy number gains and 
increased methylation. This analysis shows a wider range of increased methylation in 
the LOH and GAIN tumors compared to the neutral LOH genes. C) Gene expression 
analysis (log-fold change) of the same genes shown as a boxplot of difference in 
median expression levels of diploid tumors compared to LOH tumors, copy neutral 
tumors or copy gain tumors. This shows that tumors containing LOH and methylation 
more often have decreased expression and copy gain tumors often maintain higher 
expression.  
  
Table1. Genome-wide methylation profiles predict mutation status while gene 
expression profiles predict intrinsic subtype. Support vector machine learning 
prediction of mutation status or intrinsic subtype based on methylation profiles (medip) 
or gene expression profiles (GEM). Analysis of MeDIP data was performed on a random 
selection of 24 tumors (8 from each group) and the numbers presented are an average 
of 10 permutations of sample selections such that all tumors were used in the analysis. 
These numbers do not always add up to 8 due to the averaging across the 10 
permutations. GEM analysis was performed on a random selection of 20 tumors (10 
from each group) and the numbers presented are an average of 10 permutations of 
sample selections such that all tumors were used in the analysis. Analysis could only be 
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performed on the two largest groups (basal and luminal A). Percent gain represents the 
improvement of the prediction over random chance (%expected). 
 
Tables 
Table 1.   
meDIP predicted 
      given BRCA1 BRCA2 BRCAx %error %predicted %expected %gain 
BRCA1 6.5 0.6 1.2 18.8 81.3 33.3 47.9 
BRCA2 0.8 5.5 1.7 31.3 68.8 33.3 35.4 
BRCAx 0.8 2.7 5.1 36.3 63.8 33.3 30.4 
        meDIP predicted 
      given Basal LumA 
 
%error %predicted %expected %gain 
Basal 5.8 4.3 
 
42.0 58.0 50.0 8.0 
LumA 5 5.1 
 
49.0 51.0 50.0 1.0 
        
        GEM predicted 
      given BRCA1 BRCA2 BRCAx %error %predicted %expected %gain 
BRCA1 7.1 0.9 0 11.3 88.8 33.3 55.4 
BRCA2 0.3 4.5 3.2 43.8 56.3 33.3 22.9 
BRCAx 1.9 3.8 2.3 71.3 28.8 33.3 -4.6 
        GEM predicted 
      given Basal LumA 
 
%error %predicted %expected %gain 
Basal 10 0 
 
0.0 100.0 50.0 50.0 
LumA 0 10 
 
0.0 100.0 50.0 50.0 
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Supplementary Data 
 
Supplementary Figure 1. Validation of meDIP microarray analysis. A) Pre-
amplification analysis of meDIP enrichment by quantitative PCR for known methylated 
sequences (Alpha Sat repeats and spiked in methylated control) and known 
unmethylated sequences (GAPDH promoter and spiked in unmethylated control). Y-axis 
represents fold-change over total input. B) Post-amplification analysis of meDIP 
enrichment by quantitative PCR. C) Pyrosequencing-based methylation analysis of an 
unmethylated gene GRHL2 (n=6), a methylated gene DHX33 (n=6) and the IGF2 
imprinted region DMR0 (n=33) showing strong correlation with the meDIP microarray t-
values (y-axis). D) Pyrosequencing-based methylation analysis of the RASSF1A 
promoter shows strong correlation with the microarray t-values in 33 tumor samples.   
 
Supplementary Figure 2. Separation of genes by CpG ratio. All transcription start 
sites were divided into low-CpG content promoters (LCP), intermediate-CpG content 
promoters (ICP) and high-CpG content promoters (HCP) as previously described 16. X-
axis represents CpG ratio. 
 
Supplementary Figure 3. DNA methylation profiles of BRCA1, BRCA2 and BRCAx 
tumors. A) Pyrosequencing-based methylation analysis of RASSF1A, SGK1, 
DA103059, GRAMD1C, LRRC55 and LHCGR in 33 tumors. The median methylation 
levels are indicated by the red line. Genomic locations for the regions presented are 
from Human Mar. 2006 Assembly (hg18). Stars indicate statistically significant 
Supplemental Text and Figures
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differences between groups at p<0.05 and p<0.01 as indicated, wilcoxon signed rank 
sum test. B) Pyrosequencing-based methylation analysis in 47 FFPE tumor DNA 
samples. 
 
Supplementary Figure 4. Fine mapping of increased methylation of ESR1 in ER 
negative BRCA1 mutation carriers. A) UCSC genome browser image of ESR1 CpG 
island and flanking regions. B) Probe-wise analysis of DNA methylation across the 
ESR1 CpG island identifies two candidate regions of increased methylation in ER 
negative BRCA1 mutation carriers (white boxes, n=9) compared to ER negative non-
BRCA1 mutation carriers (red boxes, n=4). C) Pyrosequencing-based methylation 
analysis of region 1 (chr6:152171022-152171141) and region 2 (chr6:152171256-
152171402) validates the significant increase in methylation of region 2 in ER negative 
tumors from BRCA1 mutation carriers compared to ER negative tumors from non-
BRCA1 mutation carriers. 
 
Supplementary Figure 5. Copy Number versus Methylation in BRCA1, BRCA2 and 
BRCAx tumors. Heatmap of median methylation levels (medip t-values) for each gene 
(n=16237) broken down into copy number groups (y-axis) of tumors showing 
homozygous deletion, loss of heterozygosity, normal diploidy, copy neutral LOH or 
gains in BRCA1 (A), BRCA2 (B) or BRCAx tumors (C).  
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Supplementary Tables (see attached Excel spreadsheets) 
 
Supplementary Table 1: Tumor Information 
Supplementary Table 2: Primers used in this study  
Supplementary Table 3: List of 156 genes that differentiate BRCAx subgroups 
Supplementary Table 4: List of frequently hypermethylated genes in breast cancer 
Supplementary Table 5: Chi squared analysis of methylation versus copy number 
 LOH Copy neutral LOH GAIN 
Higher Methylation 
(vs diploid) 
600 125 1033 
Lower Methylation 
(vs diploid) 
39 112 48 
2 = 407.3 ; p<2.2 e-16 
 
Supplementary Table 6: List of all genes correlation between methylation level and 
gene expression level.  
 
 
